{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:15:42Z","timestamp":1761844542819,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T00:00:00Z","timestamp":1433808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T00:00:00Z","timestamp":1433808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/tpj.2015.41","type":"journal-article","created":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T10:02:03Z","timestamp":1433844123000},"page":"266-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genetic risk of subsequent esophageal cancer in lymphoma and breast cancer long-term survival patients: a pilot study"],"prefix":"10.1038","volume":"16","author":[{"given":"E","family":"Boldrin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-0006","authenticated-orcid":false,"given":"E","family":"Rumiato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6515-5482","authenticated-orcid":false,"given":"M","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Rugge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Cagol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Chiarion-Sileni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ruol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Gusella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Pasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Saggioro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,9]]},"reference":[{"key":"BFtpj201541_CR1","first-page":"289","volume":"9","author":"F Fekete","year":"1994","unstructured":"Fekete F, Mosnier H, Belghiti J, Uribe M, Sauvanet A . Esophageal cancer after mediastinal irradiation. Dysphagia 1994; 9: 289\u2013291.","journal-title":"Dysphagia"},{"key":"BFtpj201541_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/jjco\/29.3.164","volume":"29","author":"O Micke","year":"1999","unstructured":"Micke O, Schafer U, Glashorster M, Prott FJ, Willich N . Radiation-induced esophageal carcinoma 30 years after mediastinal irradiation: case report and review of the literature. Jpn J Clin Oncol 1999; 29: 164\u2013170.","journal-title":"Jpn J Clin Oncol"},{"key":"BFtpj201541_CR3","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","volume":"366","author":"M Clarke","year":"2005","unstructured":"Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087\u20132106.","journal-title":"Lancet"},{"key":"BFtpj201541_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/aje\/kwi050","volume":"161","author":"LB Zablotska","year":"2005","unstructured":"Zablotska LB, Chak A, Das A, Neugut AI . Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol 2005; 161: 330\u2013337.","journal-title":"Am J Epidemiol"},{"key":"BFtpj201541_CR5","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/annonc\/mds144","volume":"23","author":"LM Morton","year":"2012","unstructured":"Morton LM, Gilbert ES, Hall P, Andersson M, Joensuu H, Vaalavirta L . Risk of treatment-related esophageal cancer among breast cancer survivors. Ann Oncol 2012; 23: 3081\u20133091.","journal-title":"Ann Oncol"},{"key":"BFtpj201541_CR6","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1182\/blood-2006-07-037853","volume":"109","author":"AG Smith","year":"2007","unstructured":"Smith AG, Worrillow LJ, Allan JM . A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia. Blood 2007; 109: 1233\u20131236.","journal-title":"Blood"},{"key":"BFtpj201541_CR7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1182\/blood-2007-11-126508","volume":"112","author":"NA Ellis","year":"2008","unstructured":"Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008; 112: 741\u2013749.","journal-title":"Blood"},{"key":"BFtpj201541_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2004.06.016","volume":"221","author":"FF Parl","year":"2005","unstructured":"Parl FF . Glutathione S-transferase genotypes and cancer risk. Cancer Lett 2005; 221: 123\u2013129.","journal-title":"Cancer Lett"},{"key":"BFtpj201541_CR9","doi-asserted-by":"publisher","first-page":"9582","DOI":"10.1158\/0008-5472.CAN-05-1460","volume":"65","author":"Y Hong","year":"2005","unstructured":"Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005; 65: 9582\u20139587.","journal-title":"Cancer Res"},{"key":"BFtpj201541_CR10","doi-asserted-by":"publisher","first-page":"e47325","DOI":"10.1371\/journal.pone.0047325","volume":"7","author":"K Proestling","year":"2012","unstructured":"Proestling K, Hebar A, Pruckner N, Marton E, Vinatzer U, Schreiber M . The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLoS One 2012; 7: e47325.","journal-title":"PLoS One"},{"key":"BFtpj201541_CR11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/ijc.28123","volume":"133","author":"K Paszkowska-Szczur","year":"2013","unstructured":"Paszkowska-Szczur K, Scott RJ, Serrano-Fernandez P, Mirecka A, Gapska P, Gorski B et al. Xeroderma pigmentosum genes and melanoma risk. Int J Cancer 2013; 133: 1094\u20131100.","journal-title":"Int J Cancer"},{"key":"BFtpj201541_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/jnci\/djn437","volume":"101","author":"P Vineis","year":"2009","unstructured":"Vineis P, Manuguerra M, Kavvoura FK, Guarrera S, Allione A, Rosa F et al. A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst 2009; 101: 24\u201336.","journal-title":"J Natl Cancer Inst"},{"key":"BFtpj201541_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/FPC.0b013e3283653afc","volume":"23","author":"E Rumiato","year":"2013","unstructured":"Rumiato E, Cavallin F, Boldrin E, Cagol M, Alfieri R, Basso D et al. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin\/5-FU-based neoadjuvant therapy. Pharmacogenet Genomics 2013; 23: 597\u2013604.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201541_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ctrv.2012.02.004","volume":"38","author":"D Borchiellini","year":"2012","unstructured":"Borchiellini D, Etienne-Grimaldi MC, Thariat J, Milano G . The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes. Cancer Treat Rev 2012; 38: 737\u2013759.","journal-title":"Cancer Treat Rev"},{"key":"BFtpj201541_CR15","first-page":"1513","volume":"11","author":"EL Goode","year":"2002","unstructured":"Goode EL, Ulrich CM, Potter JD . Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1513\u20131530.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFtpj201541_CR16","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1186\/1471-230X-12-137","volume":"12","author":"Z Wang","year":"2012","unstructured":"Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y . Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum\/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol 2012; 12: e137.","journal-title":"BMC Gastroenterol"},{"key":"BFtpj201541_CR17","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1186\/bcr1682","volume":"9","author":"T Toyama","year":"2007","unstructured":"Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 2007; 9: R34.","journal-title":"Breast Cancer Res"},{"key":"BFtpj201541_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/01.fpc.0000204997.84182.69","volume":"16","author":"P Wegman","year":"2006","unstructured":"Wegman P, Stal O, Askmalm MS, Nordenskjold B, Rutqvist LE, Wingren S . p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. Pharmacogenet Genomics 2006; 16: 347\u2013351.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201541_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/carcin\/bgp096","volume":"30","author":"ME Zafereo","year":"2009","unstructured":"Zafereo ME, Sturgis EM, Liu Z, Wang LE, Wei Q, Li G . Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis 2009; 30: 997\u20131002.","journal-title":"Carcinogenesis"},{"key":"BFtpj201541_CR20","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1097\/01.mlg.0000183736.96004.f7","volume":"115","author":"TJ Gal","year":"2005","unstructured":"Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM . DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope 2005; 115: 2221\u20132231.","journal-title":"Laryngoscope"},{"key":"BFtpj201541_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11605-011-1700-x","volume":"16","author":"R Metzger","year":"2012","unstructured":"Metzger R, Warnecke-Eberz U, Alakus H, Kutting F, Brabender J, Vallbohmer D et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg 2012; 16: 26\u201334.","journal-title":"J Gastrointest Surg"},{"key":"BFtpj201541_CR22","first-page":"843","volume":"9","author":"P Chen","year":"2000","unstructured":"Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 2000; 9: 843\u2013847.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFtpj201541_CR23","first-page":"555","volume":"16","author":"JJ Yu","year":"2000","unstructured":"Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F et al. Comparison of two human ovarian carcinoma cell lines (A2780\/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000; 16: 555\u2013560.","journal-title":"Int J Oncol"},{"key":"BFtpj201541_CR24","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.2217\/pgs.11.109","volume":"12","author":"E Giovannetti","year":"2011","unstructured":"Giovannetti E, Pacetti P, Reni M, Leon LG, Mambrini A, Vasile E et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics 2011; 12: 1641\u20131652.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201541_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.semradonc.2010.05.003","volume":"20","author":"MB Parliament","year":"2010","unstructured":"Parliament MB, Murray D . Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin Radiat Oncol 2010; 20: 232\u2013240.","journal-title":"Semin Radiat Oncol"},{"key":"BFtpj201541_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.mrfmmm.2008.10.014","volume":"667","author":"O Popanda","year":"2009","unstructured":"Popanda O, Marquardt JU, Chang-Claude J, Schmezer P . Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat Res 2009; 667: 58\u201369.","journal-title":"Mutat Res"},{"key":"BFtpj201541_CR27","doi-asserted-by":"publisher","first-page":"12754","DOI":"10.1073\/pnas.94.24.12754","volume":"94","author":"DM Wilson 3rd","year":"1997","unstructured":"Wilson DM 3rd, Thompson LH . Life without DNA repair. Proc Natl Acad Sci USA 1997; 94: 12754\u201312757.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201541_CR28","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1182\/blood-2002-04-1152","volume":"100","author":"C Seedhouse","year":"2002","unstructured":"Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E . The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002; 100: 3761\u20133766.","journal-title":"Blood"},{"key":"BFtpj201541_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3109\/10409239509083491","volume":"30","author":"JD Hayes","year":"1995","unstructured":"Hayes JD, Pulford DJ . The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445\u2013600.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"BFtpj201541_CR30","doi-asserted-by":"publisher","first-page":"11592","DOI":"10.1073\/pnas.191211198","volume":"98","author":"JM Allan","year":"2001","unstructured":"Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001; 98: 11592\u201311597.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201541_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/tpj.2009.45","volume":"10","author":"AV Khrunin","year":"2010","unstructured":"Khrunin AV, Moisseev A, Gorbunova V, Limborska S . Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010; 10: 54\u201361.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201541_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1044-579X(02)00099-8","volume":"13","author":"D Michael","year":"2003","unstructured":"Michael D, Oren M . The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13: 49\u201358.","journal-title":"Semin Cancer Biol"},{"key":"BFtpj201541_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ng1093","volume":"33","author":"P Dumont","year":"2003","unstructured":"Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M . The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 357\u2013365.","journal-title":"Nat Genet"},{"key":"BFtpj201541_CR34","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1038\/sj.onc.1207428","volume":"23","author":"A Sullivan","year":"2004","unstructured":"Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23: 3328\u20133337.","journal-title":"Oncogene"},{"key":"BFtpj201541_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cell.2004.11.022","volume":"119","author":"GL Bond","year":"2004","unstructured":"Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591\u2013602.","journal-title":"Cell"},{"key":"BFtpj201541_CR36","doi-asserted-by":"publisher","first-page":"26776","DOI":"10.1074\/jbc.M505203200","volume":"280","author":"NC Arva","year":"2005","unstructured":"Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005; 280: 26776\u201326787.","journal-title":"J Biol Chem"},{"key":"BFtpj201541_CR37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2217\/14622416.6.6.615","volume":"6","author":"JM Allan","year":"2005","unstructured":"Allan JM, Rabkin CS . Genetic susceptibility to iatrogenic malignancy. Pharmacogenomics 2005; 6: 615\u2013628.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201541_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2156-9-36","volume":"9","author":"I Menashe","year":"2008","unstructured":"Menashe I, Rosenberg PS, Chen BE . PGA: power calculator for case-control genetic association analyses. BMC Genet 2008; 9: 36.","journal-title":"BMC Genet"},{"key":"BFtpj201541_CR39","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.3748\/wjg.v18.i45.6521","volume":"18","author":"J Chai","year":"2012","unstructured":"Chai J, Jamal MM . Esophageal malignancy: a growing concern. World J Gastroenterol 2012; 18: 6521\u20136526.","journal-title":"World J Gastroenterol"},{"key":"BFtpj201541_CR40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/archsurg.2008.574","volume":"144","author":"A Ruol","year":"2009","unstructured":"Ruol A, Castoro C, Portale G, Cavallin F, Sileni VC, Cagol M et al. Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution. Arch Surg 2009; 144: 247\u2013254.","journal-title":"Arch Surg"},{"key":"BFtpj201541_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrclinonc.2013.41","volume":"10","author":"LB Travis","year":"2013","unstructured":"Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK . Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013; 10: 289\u2013301.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFtpj201541_CR42","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1200\/JCO.2012.41.8681","volume":"30","author":"ME Wood","year":"2012","unstructured":"Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB . Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol 2012; 30: 3734\u20133745.","journal-title":"J Clin Oncol"},{"key":"BFtpj201541_CR43","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/nrc1749","volume":"5","author":"JM Allan","year":"2005","unstructured":"Allan JM, Travis LB . Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005; 5: 943\u2013955.","journal-title":"Nat Rev Cancer"},{"key":"BFtpj201541_CR44","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nm.2407","volume":"17","author":"T Best","year":"2011","unstructured":"Best T, Li D, Skol AD, Kirchhoff T, Jackson SA, Yasui Y et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin\u2019s lymphoma. Nat Med 2011; 17: 941\u2013943.","journal-title":"Nat Med"},{"key":"BFtpj201541_CR45","doi-asserted-by":"publisher","first-page":"e0117070","DOI":"10.1371\/journal.pone.0117070","volume":"10","author":"E Boldrin","year":"2015","unstructured":"Boldrin E, Rumiato E, Fassan M, Cappellesso R, Rugge M, Chiarion-Sileni V et al. Genetic features of metachronous esophageal cancer developed in Hodgkin\u2019s lymphoma or breast cancer long-term survivors: an exploratory study. PLoS One 2015; 10: e0117070.","journal-title":"PLoS One"},{"key":"BFtpj201541_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/aje\/kwi018","volume":"161","author":"S Benhamou","year":"2005","unstructured":"Benhamou S, Sarasin A . ERCC2 \/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 2005; 161: 1\u201314.","journal-title":"Am J Epidemiol"},{"key":"BFtpj201541_CR47","doi-asserted-by":"publisher","first-page":"e35220","DOI":"10.1371\/journal.pone.0035220","volume":"7","author":"YY Hu","year":"2012","unstructured":"Hu YY, Yuan H, Jiang GB, Chen N, Wen L, Leng WD et al. Associations between XPD Asp312Asn polymorphism and risk of head and neck cancer: a meta-analysis based on 7,122 subjects. PLoS One 2012; 7: e35220.","journal-title":"PLoS One"},{"key":"BFtpj201541_CR48","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/carcin\/bgm020","volume":"28","author":"G Liu","year":"2007","unstructured":"Liu G, Zhou W, Yeap BY, Su L, Wain JC, Poneros JM et al. XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk. Carcinogenesis 2007; 28: 1254\u20131258.","journal-title":"Carcinogenesis"},{"key":"BFtpj201541_CR49","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/carcin\/bgp058","volume":"30","author":"J Pan","year":"2009","unstructured":"Pan J, Lin J, Izzo JG, Liu Y, Xing J, Huang M et al. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis 2009; 30: 785\u2013792.","journal-title":"Carcinogenesis"},{"key":"BFtpj201541_CR50","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s10552-008-9171-4","volume":"19","author":"D Tse","year":"2008","unstructured":"Tse D, Zhai R, Zhou W, Heist RS, Asomaning K, Su L et al. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control 2008; 19: 1077\u20131083.","journal-title":"Cancer Causes Control"},{"key":"BFtpj201541_CR51","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/carcin\/bgl017","volume":"27","author":"W Ye","year":"2006","unstructured":"Ye W, Kumar R, Bacova G, Lagergren J, Hemminki K, Nyren O . The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden. Carcinogenesis 2006; 27: 1835\u20131841.","journal-title":"Carcinogenesis"},{"key":"BFtpj201541_CR52","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.7314\/APJCP.2012.13.7.3299","volume":"13","author":"XL Duan","year":"2012","unstructured":"Duan XL, Gong H, Zeng XT, Ni XB, Yan Y, Chen W et al. Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev 2012; 13: 3299\u20133303.","journal-title":"Asian Pac J Cancer Prev"},{"key":"BFtpj201541_CR53","doi-asserted-by":"publisher","first-page":"16765","DOI":"10.3748\/wjg.v20.i44.16765","volume":"20","author":"R Yang","year":"2014","unstructured":"Yang R, Zhang C, Malik A, Shen ZD, Hu J, Wu YH . Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies. World J Gastroenterol 2014; 20: 16765\u201316773.","journal-title":"World J Gastroenterol"},{"key":"BFtpj201541_CR54","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/FPC.0b013e3280115e63","volume":"17","author":"KJ Wolfe","year":"2007","unstructured":"Wolfe KJ, Wickliffe JK, Hill CE, Paolini M, Ammenheuser MM, Abdel-Rahman SZ . Single nucleotide polymorphisms of the DNA repair gene XPD\/ERCC2 alter mRNA expression. Pharmacogenet Genomics 2007; 17: 897\u2013905.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201541_CR55","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/carcin\/21.4.551","volume":"21","author":"RM Lunn","year":"2000","unstructured":"Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000; 21: 551\u2013555.","journal-title":"Carcinogenesis"},{"key":"BFtpj201541_CR56","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1667\/RR3400","volume":"164","author":"J Rzeszowska-Wolny","year":"2005","unstructured":"Rzeszowska-Wolny J, Polanska J, Pietrowska M, Palyvoda O, Jaworska J, Butkiewicz D et al. Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat Res 2005; 164: 132\u2013140.","journal-title":"Radiat Res"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201541.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201541","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201541.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:11:29Z","timestamp":1647947489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,9]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFtpj201541"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2015.41","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"type":"print","value":"1470-269X"},{"type":"electronic","value":"1473-1150"}],"subject":[],"published":{"date-parts":[[2015,6,9]]},"assertion":[{"value":"8 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}